Efficacy and muscle safety assessment of fukutin-related protein gene therapy

Limb-girdle muscular dystrophy type R9 (LGMDR9) is a muscle-wasting disease that begins in the hip and shoulder regions of the body. This disease is caused by mutations in fukutin-related protein (FKRP), a glycosyltransferase critical for maintaining muscle cell integrity. Here we investigated potential gene therapies for LGMDR9 containing an FKRP expression construct with untranslated region (UTR) modifications. Initial studies treated an aged dystrophic mouse model (FKRPP448L) with adeno-associated virus vector serotype 6 (AAV6). Grip strength improved in a dose- and time-dependent manner, injected mice exhibited fewer central nuclei and serum creatine kinase levels were 3- and 5-fold lower compared to those in non-injected FKRPP448L mice. Treatment also partially stabilized the respiratory pattern during exercise and improved treadmill running, partially protecting muscle from exercise-induced damage. Western blotting of C2C12 myotubes using a novel rabbit antibody confirmed heightened translation with the UTR modifications. We further explored the question of FKRP toxicity in wild-type mice using high doses of two additional muscle-tropic capsids: AAV9 and AAVMYO1. No toxic effects were detected with either therapeutic agent. These data further support the feasibility of gene therapy to treat LGMDR9.

National biosecurity approaches, plans and programmes in response to diseases in farmed aquatic animals: evolution, effectiveness and the way forward

The rapid increase in aquaculture production and trade, and increased attention to the negative effects of disease, are becoming stimuli for developing national biosecurity strategies for farmed fisheries, for which the World Organisation for Animal Health (OIE) Aquatic Animal Health Code and Manual of Diagnostic Tests for Aquatic Animals serve as an excellent framework. Using examples from a few countries and selected diseases, this paper provides a general overview of the development of approaches to implementing biosecurity strategies, including those emerging in the national legislation and regulations of some countries, and those being initiated by industries themselves. The determination of disease status in different epidemiological units (from a farm to a nation), appropriate approaches for preventing the introduction of disease and developing contingencies for disease control and eradication are also discussed. Important to the effectiveness of such strategies are provision of financial, personnel and other resources to implement them, including incentives such as indemnification or compensation in eradication programmes, and practical linkage to regulatory or government policy initiatives.

Multi-platform, multi-site instrumentation and reagent standardization

As flow cytometry laboratories involve themselves in more multi-site domestic and international clinical trial and research studies, it becomes imperative that they develop and adopt qualitative and quantitative standardization. This standardization does not need to be at the instrument-design level but it may evolve from a general consensus on instrument setup, internationally accepted standardized procedures, and quantitative fluorescence intensity units. Instrument condition, age, and setup as well as model and manufacturer all affect the overall instrument performance and quantitative characteristics. Therefore, when working with multiple instruments, platforms, or sites, a standard window of analysis is essential. Furthermore, we should strive to characterize instrument performance and quantitative indices so that data can be compared directly. The same thoughts and ideals hold true for standardizing procedures and reagents. Clones, conjugation, incubation times, pH, temperature, and other environmental conditions all combine to affect the qualitative and quantitative cellular indices that we are attempting to measure. Data are presented that illustrates why standardization is needed and how we have attempted to achieve it in our laboratories.